Impact of rheumatoid arthritis in Turkey: A questionnaire study
dc.contributor.author | Direskeneli H. | |
dc.contributor.author | Akkoç N. | |
dc.contributor.author | Bes C. | |
dc.contributor.author | Çakir N. | |
dc.contributor.author | Çefle A. | |
dc.contributor.author | Çobankara V. | |
dc.contributor.author | Dalkiliç E. | |
dc.contributor.author | Dinç A. | |
dc.contributor.author | Ertenli I. | |
dc.contributor.author | Gül A. | |
dc.contributor.author | Hamuryudan V. | |
dc.contributor.author | Inanç M. | |
dc.contributor.author | Kalyoncu U. | |
dc.contributor.author | Karaaslan Y. | |
dc.contributor.author | Kaşifoǧlu T. | |
dc.contributor.author | Keser G. | |
dc.contributor.author | Keskin G. | |
dc.contributor.author | Kisacik B. | |
dc.contributor.author | Kiraz S. | |
dc.contributor.author | Masatlioǧlu S. | |
dc.contributor.author | Onat A.M. | |
dc.contributor.author | Özbek S. | |
dc.contributor.author | Öztürk M.A. | |
dc.contributor.author | Pamuk Ö.N. | |
dc.contributor.author | Pay P. | |
dc.contributor.author | Pirildar T. | |
dc.contributor.author | Sayarlioǧlu M. | |
dc.contributor.author | Şenel S. | |
dc.contributor.author | Şentürk T. | |
dc.contributor.author | Taşan D. | |
dc.contributor.author | Terzioǧlu E. | |
dc.contributor.author | Yazici A. | |
dc.contributor.author | Yücel E. | |
dc.date.accessioned | 2025-04-10T11:13:10Z | |
dc.date.available | 2025-04-10T11:13:10Z | |
dc.date.issued | 2014 | |
dc.description.abstract | Objective: Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods: The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results: The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion: In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study. © Clinical and Experimental Rheumatology 2014. | |
dc.identifier.uri | http://hdl.handle.net/20.500.14701/49789 | |
dc.publisher | Clinical and Experimental Rheumatology S.A.S. | |
dc.title | Impact of rheumatoid arthritis in Turkey: A questionnaire study | |
dc.type | Article |